L-Leucine, N-((1,1-dimethylethoxy)carbonyl)- → Tert-butyl(s)-1-((3ar,4r,6as)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate

Participants

Reaction Steps

The title compound was prepared by substituting N-(tert-butoxycarbonyl)-N-methyl-L-norvaline for N-(tert-butoxycarbonyl)-L-leucine and (3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in the procedure described in Example 221: 1H NMR (400 MHz, pyridine-d5) δ ppm 7.40 (d, J=7.4, 2H), 7.34 (t, J=7.5, 2H), 7.25 (t, J=7.3, 1H), 4.79-4.68 (m, 1H), 4.44-4.32 (m, 1H), 3.82 (d, J=13.2, 1H), 3.36 (d, J=13.0, 1H), 2.94 (s, 3H), 2.80-2.65 (m, 2H), 2.46 (s, 1H), 2.35 (dd, J=9.2, 2.7, 1H), 2.31-2.25 (m, 2H), 1.99 (dt, J=14.0, 7.0, 1H), 1.83-1.72 (m, 2H), 1.70-1.56 (m, 2H), 1.49 (d, J=4.5, 1H), 1.48 (s, 9H), 1.41-1.23 (m, 3H), 0.89 (t, J=7.4, 3H); MS (ESI+) m/z 430 (M+H)+.

Provenance & Evidence